The emergence of dual-action receptor agonists in the approach of type 2 diabetes and obesity has sparked considerable interest, particularly regarding retatrutide and tirzepatide. While both medications target both https://arranylbf768437.blue-blogs.com/46697914/retatrutide-vs-tirzepatide-a-comparative-analysis